[Pharmacokinetics of KRN 8602 in cancer patients].


The pharmacokinetic properties of KRN 8602, an anthracycline compound, was studied by HPLC following intravenous administration of KRN 8602 to cancer patients. The results were as follows. (1) The plasma concentration-time curve declined as a triphasic function (alpha, beta, gamma) (t1/2 (alpha) = 0.02910, +/- 0.0054 hr, t1/2 (beta) = 0.704 +/- 0.319 hr, t1… (More)


Cite this paper

@article{Majima1991PharmacokineticsOK, title={[Pharmacokinetics of KRN 8602 in cancer patients].}, author={Hideyuki Majima and Hisashi Shinkai}, journal={Gan to kagaku ryoho. Cancer & chemotherapy}, year={1991}, volume={18 15}, pages={2589-95} }